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Quality Improvement Proposal
• Chemotherapy in the United States is largely 
administered in outpatient infusion centers.
• Home administration of chemotherapy has been 
demonstrated to be safe, effective and patient 
centered1-3.
• We propose to develop and scale a home based 
chemotherapy program for patients at Thomas 
Jefferson University. 
• Prior to implementation, we systematically 
reviewed all medications administered in the 
outpatient infusion center for feasibility of 
administration in the home setting. 
Intervention
• Each medication administered in the outpatient 
infusion center was reviewed and barriers to home 
infusion were identified. Barriers included4-6:
o Route and duration of administration,
o Vesicant status, 
o Emetogenic potential, and 
o Stability at room temperature.
• Scoring was determined by a multidisciplinary team 
of pharmacists and oncologists (see Table 1).
• Higher scores indicated greater potential for home 
administration.
Measurement and Results Next Steps and Lessons Learned
• Based on our criteria, most medications can be 
administered in the home setting.
• A major barrier to administration at home is 
stability of medications at room temperature. 
o This issue can be addressed by 
transporting and storing the medication in 
a refrigerated container. 
• Expectedly, injectable drugs and medications 
with short infusion times that are stable at room 
temperature would be easiest to administer at 
home. 
• Further analysis is ongoing to assess the financial 
feasibility. 
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Next Steps and Le sons Learned
Variables Score
Route of Administration 
SubQ/IM
IV
0
1
Duration of Administration
> 24 hours
> 90 minutes, < 24 hours
> 60 minutes, < 90 minutes
< 60 minutes
2
0
1
2
Vesicant Status
Yes
No
-1
1
Emetogenic Potential
High
Moderate
Low
Minimal
-1
0
1
2
Stability at Room Temperature 
Not Stable
< 4 hours
> 4 hours, < 8 hours
> 8 hours, < 12 hours
> 12 hours
-2
-1
0
1
2
• 100 medications were reviewed.
• The highest possible score was 8; the lowest 
possible score was -4. Agents ranged with 
scores from 8 (fulvestrant) to -1 (dactinomycin), 
with a median score of 4. 
• The largest factor lowering the score was 
stability at room temperature; score of -2 and -1 
in 19 and 18 medications respectively.
